Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials

Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann O'Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Bradley H Pollock, Gregory Reaman, David R. Freyer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin-induced hearing loss (CIHL) is a common, clinically significant side effect with life-long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently completed Children's Oncology Group studies focused on the measurement and prevention of CIHL. The purpose of this paper was to gain insights from ACCL05C1 and ACCL0431, the first published cooperative group studies dedicated solely to CIHL, to inform the design of future pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for preventing CIHL, but their successful development must overcome a unique constellation of methodological challenges related to translating preclinical research into clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues particularly important for children include use of appropriate methods for hearing assessment and CIHL severity grading, and use of trial designs that are well-informed by preclinical models and suitable for relatively small sample sizes. Increasing interest has made available new funding opportunities for expanding this urgently needed research.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hearing Loss
Cisplatin
Clinical Trials
Pediatrics
Research
Sample Size
Hearing
Neoplasms

Keywords

  • Cisplatin
  • Hearing loss
  • Pediatric
  • Prevention
  • Study design

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Minasian, L. M., Frazier, A. L., Sung, L., O'Mara, A., Kelaghan, J., Chang, K. W., ... Freyer, D. R. (Accepted/In press). Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials. Cancer Medicine. https://doi.org/10.1002/cam4.1563

Prevention of cisplatin-induced hearing loss in children : Informing the design of future clinical trials. / Minasian, Lori M.; Frazier, A. Lindsay; Sung, Lillian; O'Mara, Ann; Kelaghan, Joseph; Chang, Kay W.; Krailo, Mark; Pollock, Bradley H; Reaman, Gregory; Freyer, David R.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Minasian, LM, Frazier, AL, Sung, L, O'Mara, A, Kelaghan, J, Chang, KW, Krailo, M, Pollock, BH, Reaman, G & Freyer, DR 2018, 'Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials', Cancer Medicine. https://doi.org/10.1002/cam4.1563
Minasian, Lori M. ; Frazier, A. Lindsay ; Sung, Lillian ; O'Mara, Ann ; Kelaghan, Joseph ; Chang, Kay W. ; Krailo, Mark ; Pollock, Bradley H ; Reaman, Gregory ; Freyer, David R. / Prevention of cisplatin-induced hearing loss in children : Informing the design of future clinical trials. In: Cancer Medicine. 2018.
@article{5f85c4d7ba164af4a08f812ce7be7a75,
title = "Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trials",
abstract = "Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin-induced hearing loss (CIHL) is a common, clinically significant side effect with life-long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently completed Children's Oncology Group studies focused on the measurement and prevention of CIHL. The purpose of this paper was to gain insights from ACCL05C1 and ACCL0431, the first published cooperative group studies dedicated solely to CIHL, to inform the design of future pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for preventing CIHL, but their successful development must overcome a unique constellation of methodological challenges related to translating preclinical research into clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues particularly important for children include use of appropriate methods for hearing assessment and CIHL severity grading, and use of trial designs that are well-informed by preclinical models and suitable for relatively small sample sizes. Increasing interest has made available new funding opportunities for expanding this urgently needed research.",
keywords = "Cisplatin, Hearing loss, Pediatric, Prevention, Study design",
author = "Minasian, {Lori M.} and Frazier, {A. Lindsay} and Lillian Sung and Ann O'Mara and Joseph Kelaghan and Chang, {Kay W.} and Mark Krailo and Pollock, {Bradley H} and Gregory Reaman and Freyer, {David R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1563",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Prevention of cisplatin-induced hearing loss in children

T2 - Informing the design of future clinical trials

AU - Minasian, Lori M.

AU - Frazier, A. Lindsay

AU - Sung, Lillian

AU - O'Mara, Ann

AU - Kelaghan, Joseph

AU - Chang, Kay W.

AU - Krailo, Mark

AU - Pollock, Bradley H

AU - Reaman, Gregory

AU - Freyer, David R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin-induced hearing loss (CIHL) is a common, clinically significant side effect with life-long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently completed Children's Oncology Group studies focused on the measurement and prevention of CIHL. The purpose of this paper was to gain insights from ACCL05C1 and ACCL0431, the first published cooperative group studies dedicated solely to CIHL, to inform the design of future pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for preventing CIHL, but their successful development must overcome a unique constellation of methodological challenges related to translating preclinical research into clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues particularly important for children include use of appropriate methods for hearing assessment and CIHL severity grading, and use of trial designs that are well-informed by preclinical models and suitable for relatively small sample sizes. Increasing interest has made available new funding opportunities for expanding this urgently needed research.

AB - Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin-induced hearing loss (CIHL) is a common, clinically significant side effect with life-long ramifications, particularly for young children. ACCL05C1 and ACCL0431 are two recently completed Children's Oncology Group studies focused on the measurement and prevention of CIHL. The purpose of this paper was to gain insights from ACCL05C1 and ACCL0431, the first published cooperative group studies dedicated solely to CIHL, to inform the design of future pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for preventing CIHL, but their successful development must overcome a unique constellation of methodological challenges related to translating preclinical research into clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues particularly important for children include use of appropriate methods for hearing assessment and CIHL severity grading, and use of trial designs that are well-informed by preclinical models and suitable for relatively small sample sizes. Increasing interest has made available new funding opportunities for expanding this urgently needed research.

KW - Cisplatin

KW - Hearing loss

KW - Pediatric

KW - Prevention

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=85047752696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047752696&partnerID=8YFLogxK

U2 - 10.1002/cam4.1563

DO - 10.1002/cam4.1563

M3 - Article

AN - SCOPUS:85047752696

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -